FDA Approves Under-the-Skin Form of Drug for Maintenance Treatment of Alzheimer’s Disease

Treatment Can Be Used for At-Home Administration
On Aug. 29, the U.S. Food and Drug Administration (FDA) approved Leqembi Iqlik (lecanemab-irmb) subcutaneous (under-the-skin) injection for maintenance treatment of adults with Alzheimer’s disease. Leqembi Iqlik is indicated for patients who have completed at least 18 months of treatment with intravenous (administered into the vein) Leqembi. Leqembi Iqlik is the first amyloid beta-directed antibody approved for home administration by a patient or caregiver.